Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

A woman with multiple sclerosis (MS) has become the first person in the UK to receive a new "game-changer" 10-minute ...

The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the ...

Roche Holding's Genentech unit said the Food and Drug Administration approved its twice-yearly, subcutaneous injection treatment for patients with two types of multiple sclerosis. The treatment, ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.

The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...

It’s the latest in a years-long battle between the nonprofit, Safehouse, and the Department of Justice, which is expected to ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...